Published in Ann Surg Oncol on March 01, 2010
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (2010) 3.03
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 2.85
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65
Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J Natl Cancer Inst (2014) 2.37
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res (2010) 2.20
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist (2012) 1.88
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One (2012) 1.82
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. J Clin Oncol (2015) 1.73
Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One (2013) 1.57
Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol (2012) 1.51
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res (2013) 1.38
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res (2015) 1.29
Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One (2013) 1.21
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
A novel classification of lung cancer into molecular subtypes. PLoS One (2012) 1.13
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer (2012) 1.10
Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol (2014) 1.05
The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol (2011) 1.05
A Screening Method for the ALK Fusion Gene in NSCLC. Front Oncol (2012) 1.04
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol (2012) 1.04
Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. J Cancer Res Clin Oncol (2014) 0.98
ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation. Oncogene (2013) 0.97
Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis. PLoS One (2015) 0.96
Medical management of lung cancer: Experience in China. Thorac Cancer (2015) 0.94
Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget (2015) 0.94
ALK-immunoreactive neoplasms. Int J Clin Exp Pathol (2012) 0.93
A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. PLoS One (2013) 0.91
Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. BMC Cancer (2014) 0.90
Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement. Diagn Pathol (2014) 0.87
Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. PLoS One (2014) 0.87
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol (2016) 0.86
High prevalence of gene abnormalities in young patients with lung cancer. J Thorac Dis (2013) 0.86
Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis. PLoS One (2014) 0.86
Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population. Clinics (Sao Paulo) (2012) 0.86
Crizotinib: A comprehensive review. South Asian J Cancer (2013) 0.85
Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur Radiol (2015) 0.85
Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res (2014) 0.85
Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med (2015) 0.84
Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement. Chin J Cancer (2015) 0.83
The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy. PLoS One (2014) 0.83
Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther (2011) 0.83
Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity. BMC Cancer (2014) 0.82
Non-small cell lung cancer in never smokers: a clinical entity to be identified. Clinics (Sao Paulo) (2011) 0.82
The distinctive nature of adenocarcinoma of the lung. Onco Targets Ther (2015) 0.81
ALK gene copy number gain and its clinical significance in hepatocellular carcinoma. World J Gastroenterol (2014) 0.81
Lung cancer in never smokers. Semin Respir Crit Care Med (2011) 0.81
Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer. J Mol Model (2015) 0.81
ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res (2013) 0.81
Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. P T (2011) 0.80
Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Oncotarget (2016) 0.79
Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol (2014) 0.79
Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond. Onco Targets Ther (2015) 0.78
Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer. Oncotarget (2016) 0.77
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. J Transl Med (2016) 0.77
Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status. Biomed Rep (2014) 0.77
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci (2016) 0.77
Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype. EMBO Mol Med (2014) 0.77
Advanced non small cell lung cancer: response to microwave ablation and EGFR Status. Eur Radiol (2016) 0.76
First-line treatment of advanced ALK-positive non-small-cell lung cancer. Lung Cancer (Auckl) (2015) 0.76
ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud (2017) 0.75
Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes. Oncol Lett (2016) 0.75
ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy. World J Surg Oncol (2016) 0.75
Imaging Characteristics in ALK Fusion-Positive Lung Adenocarcinomas by Using HRCT. Ann Thorac Cardiovasc Surg (2014) 0.75
Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. Drugs Future (2011) 0.75
Ovarian metastasis from non-small cell lung cancer with ALK and EGFR mutations: A report of two cases. Oncol Lett (2016) 0.75
EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer. Oncol Lett (2015) 0.75
Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis. Oncotarget (2016) 0.75
Analysis of clinicopathological features of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non-small-cell lung cancer. Thorac Cancer (2014) 0.75
Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial". J Thorac Dis (2016) 0.75
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer. Lung Cancer (Auckl) (2012) 0.75
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. Dis Markers (2016) 0.75
Crizotinib: a breakthrough for targeted therapies in lung cancer. J Adv Pract Oncol (2012) 0.75
How and when to use genetic markers for nonsmall cell lung cancer. Curr Opin Pulm Med (2013) 0.75
Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement. Oncol Lett (2014) 0.75
Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey. Springerplus (2016) 0.75
Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma. Thorac Cancer (2014) 0.75
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer. Int J Cancer (2016) 0.75
Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations. J Cancer Res Clin Oncol (2015) 0.75
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res (2006) 4.72
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood (2012) 3.63
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract (2002) 3.30
Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes (2009) 3.27
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res (2005) 3.11
GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nat Cell Biol (2007) 2.88
Postoperative perforation in the bronchus intermedius membrane after a primary lung cancer resection. Eur J Cardiothorac Surg (2007) 2.66
Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res (2005) 2.28
Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol (2013) 2.22
A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol (2010) 2.15
Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer (2005) 1.95
Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res (2006) 1.91
Giant primary liposarcoma of the chest. Gen Thorac Cardiovasc Surg (2009) 1.89
[18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia (2005) 1.78
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol (2006) 1.75
Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. EMBO J (2005) 1.69
Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study. Mod Pathol (2002) 1.69
Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am J Physiol Endocrinol Metab (2009) 1.68
Pulmonary resection for metastasis from renal cell carcinoma. Interact Cardiovasc Thorac Surg (2008) 1.67
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood (2005) 1.67
Lung involvement in IgG4-related lymphoplasmacytic vasculitis and interstitial fibrosis: report of 3 cases and review of the literature. Am J Surg Pathol (2008) 1.65
Clinical evaluation of endoscopic bronchial occlusion with silicone spigots for the management of persistent pulmonary air leaks. Intern Med (2011) 1.61
Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant (2008) 1.61
Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol (2010) 1.61
Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res (2004) 1.60
Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res (2006) 1.53
Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl (2006) 1.52
Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation. Liver Transpl (2009) 1.50
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer (2009) 1.48
Dementia with Lewy bodies: early diagnostic challenges. Psychogeriatrics (2013) 1.48
Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol (2002) 1.48
Sacrificing the pulmonary arterial branch to the spared lobe is a risk factor of bronchopleural fistula in sleeve lobectomy after chemoradiotherapy. Eur J Cardiothorac Surg (2012) 1.46
Primary poorly differentiated monophasic synovial sarcoma of the lung. A case report with immunohistochemical and genetic studies. Pathol Res Pract (2003) 1.46
Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer (2005) 1.45
Gastric foveolar metaplasia with dysplastic changes in Brunner gland hyperplasia: possible precursor lesions for Brunner gland adenocarcinoma. Am J Surg Pathol (2005) 1.44
Addition of a neutrophil elastase inhibitor to the organ flushing solution decreases lung reperfusion injury in rat lung transplantation. Eur J Cardiothorac Surg (2007) 1.43
Snail expression is associated with a poor prognosis in malignant pleural mesotheliomas. Ann Thorac Surg (2013) 1.42
Mediastinal lymph node staging in potentially resectable non-small cell lung cancer: a prospective comparison of CT and EUS/EUS-FNA. Respiration (2009) 1.42
Videothoracoscopy-assisted surgical lung biopsy for interstitial lung diseases. Gen Thorac Cardiovasc Surg (2014) 1.41
First registry report: lung transplantation in Japan: The Japanese Society of Lung and Heart-Lung Transplantation. Gen Thorac Cardiovasc Surg (2008) 1.40
Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer (2007) 1.40
A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol (2012) 1.39
Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer (2009) 1.39
Malignant peripheral nerve sheath tumor of the parotid gland. Ann Otol Rhinol Laryngol (2003) 1.38
Salvage lung resection for non-small cell lung cancer after stereotactic body radiotherapy in initially operable patients. J Thorac Oncol (2010) 1.35
Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob Agents Chemother (2002) 1.34
Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol (2008) 1.30
Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol (2008) 1.30
Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol (2014) 1.29
Percutaneous radiofrequency ablation for clinical stage I non-small cell lung cancer: results in 20 nonsurgical candidates. J Thorac Cardiovasc Surg (2007) 1.27
Comparison of pulmonary function test and computed tomography volumetry in living lung donors. J Heart Lung Transplant (2011) 1.26
Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1. Biochem Biophys Res Commun (2005) 1.26
Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest (2005) 1.23
Prevalence of IgG antibodies specific to Toxoplasma gondii among blood donors in Recife, Northeast Brazil. Rev Inst Med Trop Sao Paulo (2003) 1.20
Schwannoma of the brachial plexus presenting as an enlarging cystic mass: report of a case. Ann Thorac Cardiovasc Surg (2008) 1.20
Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol (2008) 1.19
Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Pract (2007) 1.19
Long-term outcome of transoral organ-preserving pharyngeal endoscopic resection for superficial pharyngeal cancer. Gastrointest Endosc (2011) 1.18
FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol (2012) 1.18
Deletion of the PDGFR-beta gene affects key fibroblast functions important for wound healing. J Biol Chem (2004) 1.17
Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res (2008) 1.17
Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol (2006) 1.16
Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer (2007) 1.16
Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer (2006) 1.15
Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer (2004) 1.15
Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC). Ann Surg Oncol (2007) 1.15
Intractable pneumothorax due to bronchopleural fistula after radiofrequency ablation of lung tumors. J Vasc Interv Radiol (2007) 1.13
Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone (2007) 1.13
Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation. Proc Natl Acad Sci U S A (2014) 1.12
Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer. J Surg Oncol (2010) 1.12